Oct 19 (Reuters) - GoodRx (GDRX.O) said on Thursday it has collaborated with Sanofi (SASY.PA) to offer the drugmaker's most-prescribed insulin injection Lantus for only $35 through its digital marketplace in the U.S.
Mylan's Biologic Semglee(Insulin Glargine) Receives Approval in the U.S.
March 16 (Reuters) - Sanofi SA (SASY.PA) said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk (NOVOb.CO) and Eli Lilly and Co (LLY.N).
Glooko Inc., has partnered with Sanofi to increase their support of people living with diabetes and healthcare professionals, by integrating SoloSmart with the Glooko platform.
The Food and Drug Administration has approved Eli Lilly’s long-acting insulin Rezvoglar as an “interchangeable” product with Sanofi’s Lantus, making it the second insulin biosimilar to receive the valuable designation.
The emergence of interchangeable biosimilars since the pathway opened up has been slow. But the FDA on Thursday approved the fourth interchangeable biosimilar, which is also the second interchangeable biosimilar insulin product.
Eli's Biologic Rezvoglar (Glargine) Receives Approval in the U.S.
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.
BIOCORP (FR0012788065 – ALCOR / Eligible PEA?PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, and SANOFI announced the completion of the development of SoloSmart® today, on the opening of the EASD (European Association for the Study of Diabetes) annual meeting in Stockholm, Sweden. SoloSmart® is fully compatible with the pharmaceutical group's SoloStar® injection pens.
TORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Skylight Health Group Inc. (NASDAQ: TSXV: SLHG) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, announced that its Board of Directors has authorized, and the Company has declared, a dividend on its 9.25% Series A Cumulative Redeemable Perpetual Preferred Shares (the “Series A Preferred Shares”) for the month of October 2022. The Series A Preferred Shares trade under the “SLHGP” stock ticker symbol.